RxDoctor Payments Data

Abdul Khaleq, MD

Gastroenterology · Sacramento, CANPI 1558457960

Payments from drug & device makers

$11,560in general payments, 2019–2025

Across 81 payments — averaging $142.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Gilead$844
  • Sanofi$778
  • Takeda Pharmaceuticals U.S.A., Inc.$531
  • Janssen Scientific Affairs, LLC$451
  • Olympus America Inc.$157
  • plus $735 from 10 others

What the payments were for

  • Speaking & faculty fees$6,75058%
  • Travel & lodging$100%
  • Food & beverage$4,76241%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,560 in reported general payments places this provider in the 75th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$156,127
Medicare patients
620
Services billed
1,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cimzia (2 Pack)Certolizumab Pegol15$163,775
CreonLipase/Protease/Amylase42$115,751
Humira PenAdalimumab13$88,550
Mesalamine111$55,981
LinzessLinaclotide82$55,105
XifaxanRifaximin14$44,763
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates479$31,499
VemlidyTenofovir Alafenamide13$21,122
ZenpepLipase/Protease/Amylase16$17,228
Dexlansoprazole DrDexlansoprazole32$8,006
Sucralfate65$6,310
Mercaptopurine45$5,102
Ursodiol16$4,575
Omeprazole293$4,396
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$8,066$170,856124 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$152$44,76314 claims
GileadVemlidy$844$21,12213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →